Press Release
Exobiosphere and the Luxembourg Institute of Health Sign MoU to Advance Space-Enabled Drug Discovery
Exobiosphere SARL, a pioneering space biotechnology company based in the House of BioHealth, and the Luxembourg Institute of Health (LIH) have signed a Memorandum of Understanding (MoU) to jointly advance biomedical research and drug discovery in space. This collaboration marks a major milestone in positioning Luxembourg as a leader in space-enabled life sciences and strengthening the bridge between biotechnology and NewSpace innovation.
A New Frontier for Translational Medicine
Under this agreement, Exobiosphere will provide access to its Orbital High-Throughput Screening (OHTS) missions, an advanced standardized research platform designed to operate aboard upcoming commercial space stations such as VAST’s Haven-1. The platform enables regular orbital experiments that explore how biological systems behave in microgravity, a unique environment where cellular processes are accelerated.
Together with LIH as coordinator of the National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD), the partnership will focus on developing space grade patient-derived stem cell models and validating new therapeutic discovery pipelines for neurodegenerative diseases in orbit.
At LIH, our mission is to translate scientific discovery into better health outcomes. Exploring microgravity as a new research dimension opens exciting opportunities for translational medicine,
added Rejko Krüger of the Luxembourg Institute of Health.
Building Luxembourg’s Space Biotech Ecosystem
Beyond research, the MoU lays the foundation for broader national initiatives in space life sciences. The two institutions will co-host workshops and symposia, offer internships and training programs for Luxembourg students and postdocs, and explore funding mechanisms to sustain regular access to orbital research platforms.
“This partnership unites Luxembourg’s excellence in health research with Exobiosphere’s growing leadership in space innovation,” said Bruno Santos, Director of R&D.
“Together, we aim to accelerate the development of new Parkinsons’s treatments that could improve how we understand and fight neurodegenerative diseases.“
About the Luxembourg Institute of Health (LIH)
The Luxembourg Institute of Health (LIH) is a public biomedical research organization focused on precision health and invested in becoming a leading reference in Europe for the translation of scientific excellence into meaningful benefits for patients.
LIH places the patient at the heart of all its activities, driven by a collective obligation towards society to use knowledge and technology arising from research on patient derived data to have a direct impact on people’s health. Its dedicated teams of multidisciplinary researchers strive for excellence, generating relevant knowledge linked to immune related diseases and cancer.
The institute embraces collaborations, disruptive technology and process innovation as unique opportunities to improve the application of diagnostics and therapeutics with the long-term goal of preventing disease.
About Exobiosphere
We are revolutionizing drug discovery with our proprietary and space based Orbital High-Throughput Testing platform. By testing in space pharmaceutical and biotech companies to identify and optimize therapeutic compounds with unmatched precision and speed.
We are strategically positioned at the intersection of biotechnology and space exploration. Our partnerships with leading research institutions, launch partners and space agencies enable us to deliver groundbreaking solutions for the most complex therapeutic challenges.
Learn more: www.exobiosphere.com